South Rampart Pharma was founded and is led by a highly experienced leadership with extensive experience in biomedical research with long track records of continuous NIH funding, work with pharmaceutical and biotechnology companies, and the practice of academic clinical medicine. One of the cofounders was previously co-founder of a company that went thru a successful IPO.
South Rampart Pharma is bringing together a multidisciplinary team of scientific and pharmaceutical consultants in the Advisory Board.
This complements its own core internal expertise and will assist in the pre-clinical and regulatory development of the lead compounds.
A key member of its Advisory Board is Professor Julio Álvarez-Builla Gómez from Alcala, Spain, who is an authority medicinal chemist and has been instrumental with the fundamental chemistry behind the novel compounds.
Absent staining for nitrotyrosine, a marker for oxidative stress and liver injury, in livers from an in vivo animal model treated with our lead analgesic and antipyretic compounds